Business Description
Daiichi Sankyo Co Ltd
Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), and HER3-DXd (HER3). Enhertu entered the clinic in 2015 and received its first U.S Food and Drug Administration approval in December 2019 for third-line late-stage HER2-positive breast cancer and its high efficacy is changing the treatment landscape for HER-expressing breast cancers. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.85 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 0.95 | |||||
| Interest Coverage | 6.22 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.65 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.5 | |||||
| 3-Year EBITDA Growth Rate | 0.4 | |||||
| 3-Year EPS without NRI Growth Rate | -10 | |||||
| 3-Year FCF Growth Rate | 35.7 | |||||
| 3-Year Book Growth Rate | 3.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 41.98 | |||||
| Future 3-5Y Total Revenue Growth Rate | 15.33 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.46 | |||||
| 9-Day RSI | 50.34 | |||||
| 14-Day RSI | 49.48 | |||||
| 6-1 Month Momentum % | 28.8 | |||||
| 12-1 Month Momentum % | 63.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | |||||
| Quick Ratio | 2.79 | |||||
| Cash Ratio | 1.96 | |||||
| Days Inventory | 246.87 | |||||
| Days Sales Outstanding | 94.32 | |||||
| Days Payable | 327.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.67 | |||||
| Dividend Payout Ratio | 0.87 | |||||
| 3-Year Dividend Growth Rate | 5 | |||||
| Forward Dividend Yield % | 0.75 | |||||
| 5-Year Yield-on-Cost % | 1.06 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.69 | |||||
| Operating Margin % | 7.47 | |||||
| Net Margin % | 5.59 | |||||
| ROE % | 4.58 | |||||
| ROA % | 2.8 | |||||
| ROIC % | 6.01 | |||||
| ROC (Joel Greenblatt) % | 19.04 | |||||
| ROCE % | 4.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 124.08 | |||||
| Forward PE Ratio | 55.56 | |||||
| PE Ratio without NRI | 124.08 | |||||
| Shiller PE Ratio | 76.64 | |||||
| Price-to-Owner-Earnings | 149.1 | |||||
| PEG Ratio | 77.56 | |||||
| PS Ratio | 6.94 | |||||
| PB Ratio | 5.31 | |||||
| Price-to-Tangible-Book | 6.68 | |||||
| Price-to-Free-Cash-Flow | 90.79 | |||||
| Price-to-Operating-Cash-Flow | 50.64 | |||||
| EV-to-EBIT | 76.79 | |||||
| EV-to-Forward-EBIT | 34.91 | |||||
| EV-to-EBITDA | 46.77 | |||||
| EV-to-Forward-EBITDA | 27.42 | |||||
| EV-to-Revenue | 6.31 | |||||
| EV-to-Forward-Revenue | 5.05 | |||||
| EV-to-FCF | 82.6 | |||||
| Price-to-Projected-FCF | 4.02 | |||||
| Price-to-DCF (Earnings Based) | 5.5 | |||||
| Price-to-DCF (FCF Based) | 7.27 | |||||
| Price-to-Median-PS-Value | 3.55 | |||||
| Price-to-Graham-Number | 6.07 | |||||
| Price-to-Net-Current-Asset-Value | 15.67 | |||||
| Earnings Yield (Greenblatt) % | 1.3 | |||||
| Forward Rate of Return (Yacktman) % | 4.87 |
